Keywords: vioxx, follow-up, clears, osteoarthritis, study, mk-633, cyclo-oxygenase-2

Vioxx follow-up clears osteoarthritis study

Article | 15 November 1999

Print This

MK-633, a cyclo-oxygenase-2 inhibitor intended as a follow-up to Merck &Co's Vioxx (rofecoxib), has shown evidence of efficacy compared to ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in